Harmony Biosciences Settles Patent Dispute with Lupin

Harmony Biosciences Holdings ( (HRMY) ) has issued an update.

On June 5, 2025, Harmony Biosciences announced a settlement with Lupin Limited regarding patent infringement litigation over Lupin’s generic version of WAKIX® (pitolisant hydrochloride). The agreement allows Lupin to launch its generic product no earlier than January 2030, reinforcing Harmony’s patent position and protecting its intellectual property. This settlement highlights Harmony’s commitment to defending its innovations in sleep/wake therapeutics and strengthens its market position as it continues to develop next-generation formulations of pitolisant.

The most recent analyst rating on (HRMY) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Harmony Biosciences Holdings stock, see the HRMY Stock Forecast page.

Spark’s Take on HRMY Stock

According to Spark, TipRanks’ AI Analyst, HRMY is a Outperform.

Harmony Biosciences Holdings demonstrates strong financial performance with robust revenue and profit growth, supported by a stable balance sheet and efficient operations. The technical analysis suggests potential overbought conditions, which may pose short-term challenges. The company’s valuation is attractive, indicating potential undervaluation. Positive earnings call highlights and strategic board appointments further bolster the company’s outlook. However, increased operating expenses and seasonal dynamics warrant caution. Overall, the stock presents a solid investment opportunity with strengths in financial performance and growth potential, tempered by technical and operational considerations.

To see Spark’s full report on HRMY stock, click here.

More about Harmony Biosciences Holdings

Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases with unmet medical needs. Established in 2017 by Paragon Biosciences, LLC, and headquartered in Plymouth Meeting, Pennsylvania, the company emphasizes empathy and innovation to advance therapeutic possibilities.

Average Trading Volume: 714,376

Technical Sentiment Signal: Buy

Current Market Cap: $2.03B

For an in-depth examination of HRMY stock, go to TipRanks’ Stock Analysis page.